Some believe that the process of stem cell research involving somatic cell nuclear transfer (i.e., cloning) cannot be limited to populations of cells to be used for therapeutic purposes, but rather, will lead to reproduction, meaning the cloning or reproduction of a human being. While this outcome is far removed from current scientific knowledge and technical capabilities-it is known that there are serious health problems in animals cloned with these techniques, and all major scientific and professional associations support a ban on reproductive cloning-it remains imperative that research in this field is conducted under the highest scientific standards and ethical safeguards, similar to those applied to ESCR. (A report on the subject of somatic cell nuclear transfer is attached as an appendix.)
The AAN and the ANA recognize and respect the concerns of many of their members and the public regarding important ethical principles and values that pertain to research using human embryonic stem cells. On the one hand is respect for human life and concern about the moral status of the blastocyst (which is simultaneously the earliest form of a human embryo and the source of embryonic stem cells for research) and the fact that the process of obtaining stem cells results in the destruction of the blastocyst. While on the other hand is a strong moral obligation of physicians and scientists to pursue research that may result in beneficial treatments for diseases that affect many persons. In consideration of taking a specific position on the use of human embryonic stem cells for research, the AAN and the ANA recognize that strongly held and disparate views exist, and it is thus unlikely they can satisfy the concerns of all their members or the public.
The AAN and ANA conclude that the potential benefits of research involving human embryonic stem cells are sufficient to continue such research, that it should be conducted with strict oversight, and that the ethical safeguards developed by the NIH respect both the moral status of the embryo and public sensitivity to this issue, while ensuring that progress in critical medical research continues.
AAN AND ANA'S POSITION
The AAN and ANA have adopted the following principles relating to the use of embryonic human pluripotent stem cells:
1. We support federal and state use of the 2000 NIH Guidelines as the ethical and scientific standard for research involving human pluripotent stem cells, with certain exceptions made to address advances in somatic cell nuclear transfer (addressed in part 4). These guidelines respect both the moral status of the embryo and public sensitivity to this issue, while ensuring that progress in critical medical research will continue. The guidelines also deal appropriately with informing and obtaining consent of potential donors of material, with prohibitions on improper inducements to such donors, and with the protection of donor privacy;
2. We support expansion of federal and state funding for human pluripotent stem cell research projects to include all embryonic stem cell lines developed under appropriate ethical and scientific guidelines, not just those permitted by the 2001 presidential order. Time is valuable: although private companies are currently conducting research on pluripotent stem cells, these firms are limited in number and their research is not subject to NIH oversight, which limits scientific and ethical scrutiny and the pace of discovery. Changing federal funding policy is critical to permit the full capacity of the biomedical research workforce in the United States to discover and develop the full potential of human pluripotent stem cells under appropriate scientific and ethical guidance;
3. We support continuing research on both embryonic and adult stem cell lines. Prevailing scientific opinion is that it is far too early to know if adult stem cells have the same potential as do embryonic stem cells. For diseases that prove not to be treatable with adult stem cells, impeding human pluripotent stem cell research risks unnecessary delay for patients who may die or endure needless suffering while the effectiveness of adult stem cells is evaluated;
4. We support somatic cell nuclear transfer for purposes of creating stem cells to be used in biomedical research and treatment (therapeutic cloning), and oppose somatic cell nuclear transfer for purposes of producing a human child (reproductive cloning).
5. The AAN and ANA acknowledge differing ethical opinions on the status of embryos that cannot be resolved to the satisfaction of all through medical science alone. Consequently, the AAN and ANA recommend that ESCR and somatic cell nuclear transfer research proceed under federal oversight, ensuring that the highest quality and most promising research is conducted with utmost regard for ethical standards.
6. Because scientific knowledge regarding stem cell research is evolving, the AAN and ANA will periodically review this position and revise it as indicated. 
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Blastocyst
Structure of the embryo at day 5-an outer cell layer and an inner cell layer from which pluripotent stem cells come
Differentiation
The process by which an unspecialized cell becomes specialized into cells of various body tissues
Embryonic stem cell
A cell derived from the inner cell layer of the blastocyst
Pluripotent stem cell
A cell with the potential to generate all the cells of the human body
Stem cell
A cell that has the ability to reproduce itself for long periods or indefinitely and can give rise to specialized cells
Totipotent stem cell=fertilized egg
A cell with the potential to generate all the cells that comprise the embryo and the supporting tissue necessary for development in utero
Unipotent stem cell
A cell with the potential to develop into a single cell type
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those from which they were isolated. Although all types of stem cells are currently undergoing detailed study, most scientists agree that embryonic stem cells offer the greatest potential for the study and treatment of human disease.
Sources of embryonic stem cells
Embryonic stem cells are isolated from the inner cell layer of the blastocyst. Figure 1 depicts the isolation of stem cells from embryos created by the in vitro fertilization technique of assisted reproduction. The egg is fertilized with sperm in the laboratory and the fertilized egg is then allowed to divide for approximately 5 days to the blastocyst stage. Cells in the blastocyst form an inner cell layer surrounded by an outer cell layer. The outer cell layer gives rise to most of the supporting cells of pregnancy. Cells in the inner layer are pluripotent stem cells-they can develop into any type of human cell, but not into the supporting structures of pregnancy. Each blastocyst has about 30 cells in the inner layer. Once isolated from the inner cell layer, these cells are called embryonic stem cells. Embryonic stem cells are usually derived from donated frozen embryos. These embryos have been created by in vitro fertilization of an egg by a sperm for the treatment of infertility. Couples who decide not to implant these embryos donate them for stem cell research. Federal funding of embryonic stem cell research is currently restricted to those stem cell lines that were isolated prior to August 9, 2001 . SCNT is a novel technique to isolate embryonic stem cells. (see figure 2) In SCNT, the nucleus is removed from an egg derived from a donor through hormonal stimulation of the ovaries. A blood, skin or other cell is removed from an adult donor. The donor nucleus is inserted into the enucleated donor egg, and the egg is stimulated to divide. After 5 days, the blastocyst has formed. Stem cells from the inner cell layer are then removed from the blastocyst.
The potential of SCNT for neurological diseases
Neurological diseases are an important cause of premature death and disability. Because neural tissues have an extremely limited ability to regenerate and repair damage, there is a compelling need for novel approaches to neurodegenerative and acquired structural neurological diseases. SCNT-derived stem cells will likely contribute to several research areas besides neurotransplantation.
In particular, SCNT-derived stem cells can be used to study: (1) polygenic disorders (due to aberrant interplay of more then one gene) because the entire abnormal genome can be used to create the stem cells under study and (2) trophic factors and other signaling compounds that might offer treatment strategies for rescue or repair of damaged nervous system tissue. Moreover, stem cells might be used to carry gene therapy to targeted tissues.
In summary, stem cell research is in its infancy and it is unknown which sources of stem cells will ultimately prove most useful and cost effective for the study and treatment of neurological diseases. Consequently, the American Neurological Association and the American Academy of Neurology recommend that stem cell research, including SCNT, should proceed under federal oversight, ensuring the highest quality research with utmost regard for ethical standards.
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